Report Overview

The high prevalence of the disease creates a substantial demand for malaria treatment and control measures. The population of Africa is rapidly growing. As the population increases, so does the number of people at risk of contracting malaria. This, in turn, contributes to a higher demand for malaria treatment market during the forecast period between 2024 and 2030.

Africa Malaria Treatment Market – Industry Trends & Forecast Report, 2030

The Africa Malaria Treatment Market size was estimated at USD 108.93 Million in 2023. During the forecast period between 2024 and 2030, the Africa Malaria Treatment Market size is projected to grow at a CAGR of 3.54% reaching a value of USD 124.52 Million by 2030. The market for malaria treatments in Africa is mostly driven by the government's increased awareness campaigns and the rapid advancement of antimalarial medication development. In 2022, 59% of feverish youngsters in sub-Saharan Africa sought guidance or medical attention from a healthcare facility or practitioner. differences in the conduct of feverish children seeking care according to where they live, with urban residents more likely to be admitted than those who live in rural areas. A 17 percentage point disparity in care-seeking behavior between children from the richest homes (68%) and the poorest (51%) is another indicator of wealth-based disparities.

Malaria Treatment  – Overview

Malaria treatment encompasses a range of medical interventions aimed at combating the infectious disease caused by Plasmodium parasites transmitted through the bites of infected mosquitoes. The primary goal of malaria treatment is to eliminate the parasite from the patient's bloodstream, alleviate symptoms, and prevent the progression to severe and potentially fatal forms of the disease. Antimalarial drugs, such as artemisinin-based combination therapies (ACTs), are commonly used for this purpose. These drugs work by disrupting the lifecycle of the Plasmodium parasite within the human body. The choice of antimalarial medication may depend on factors such as the patient's age, the severity of the infection, the specific Plasmodium species causing the illness, and regional drug resistance patterns. Additionally, supportive care measures, such as management of fever, prevention of complications, and, in severe cases, hospitalization, may be incorporated into the overall treatment strategy. As malaria is a major global health concern, ongoing research and development efforts focus on improving existing treatments, developing new drugs, and addressing challenges such as drug resistance to enhance the effectiveness of malaria treatment.

Africa Malaria Treatment Market

Growth Drivers

High prevalence of malaria

Malaria is endemic in many parts of Africa, with specific regions experiencing high transmission rates. The presence of the Anopheles mosquitoes, which serve as vectors for the Plasmodium parasites causing malaria, contributes to the ongoing transmission of the disease. The tropical climate and diverse geography of many African countries create favorable conditions for the proliferation of malaria vectors. Warm temperatures and suitable breeding grounds for mosquitoes contribute to the sustained prevalence of the disease. In areas with high malaria transmission, individuals may acquire some level of immunity after repeated exposure. However, in many African regions, populations may not have acquired sufficient immunity, leading to a higher susceptibility to the disease. Despite efforts to distribute bed nets, insecticides, and other preventive interventions, access to these measures can be limited in certain regions. This results in a higher risk of malaria infection and subsequently drives the demand for treatment.

Challenges

Environmental and climate change

Changes in temperature, rainfall patterns, and humidity associated with climate change can affect the distribution and behavior of mosquitoes, particularly the Anopheles mosquitoes that transmit malaria. Warmer temperatures can extend the geographical range where these vectors can thrive, potentially leading to the spread of malaria to new areas. Climate change can influence the seasonality and intensity of malaria transmission. Shifts in temperature and precipitation patterns may lead to altered mosquito breeding cycles and changes in the timing and duration of malaria transmission seasons, making it more challenging to predict and control the disease. Environmental modifications due to climate change, such as deforestation and changes in land use, can impact the ecosystems where mosquitoes breed. These alterations may create new breeding habitats or increase the prevalence of existing ones, contributing to the persistence of malaria transmission.

Impact of Escalating Geopolitical Tensions on Africa Malaria Treatment Market

Geopolitical tensions, conflict, and instability can lead to the disruption of healthcare services. This includes the interruption of routine healthcare delivery, disease surveillance, and the distribution of essential medicines, including antimalarial drugs. Disruptions in healthcare services can exacerbate the challenges in diagnosing and treating malaria promptly. Geopolitical tensions may contribute to or result in humanitarian crises, displacing populations and straining existing healthcare systems. In such scenarios, the provision of consistent and effective malaria treatment becomes more challenging, leading to increased vulnerability among affected communities. Conflict and geopolitical tensions can damage or disrupt healthcare infrastructure, including hospitals, clinics, and laboratories. This can hinder the capacity to diagnose and treat malaria, reducing the overall effectiveness of malaria control and treatment programs.

Africa Malaria Treatment Market

Segmental Coverage

Africa Malaria Treatment Market – By Treatment

Based on treatment, the Africa Malaria Treatment Market is segmented into prescription medications, vaccines, diagnostic tests and others. The prescription medication segment is expected to hold a significant share of the market during the forecast period owing to Africa bears a significant burden of malaria cases globally, with a majority of the cases caused by the Plasmodium falciparum parasite. The necessity for effective prescription medications to treat and manage malaria is thus crucial due to the endemic nature of the disease. Efforts to improve healthcare infrastructure and accessibility in various African countries contribute to increased diagnosis and treatment of malaria cases. With better access to healthcare facilities, there is a growing demand for prescription medications as a part of comprehensive malaria treatment. Ongoing research and development initiatives focus on discovering new antimalarial drugs and improving existing ones. The introduction of novel prescription medications, including combination therapies, helps address challenges such as drug resistance and enhances the efficacy of malaria treatment.

Africa Malaria Treatment Market – By Drug Type

Based on service type, the Africa Malaria Treatment Market is segmented into branded and generic. During the forecast period, the branded segment is anticipated to hold a significant market share. Pharmaceutical companies invest in research and development to discover and manufacture new and more effective antimalarial drugs. Branded medications often result from these research efforts and are introduced into the market with the aim of providing innovative and improved treatment options. Branded medications in the malaria treatment market often come with unique formulations, delivery methods, or combinations of active ingredients. Product differentiation is a strategy employed by pharmaceutical companies to set their branded drugs apart from generic alternatives and gain a competitive edge. Branded medications, especially those with a history of effectiveness and safety, tend to build brand recognition and trust among healthcare providers and patients. This trust can influence prescribing patterns, leading to the continued growth of branded medications in the market.

Africa Malaria Treatment Market – By Route of Administration

Based on route of administration, the Africa Malaria Treatment Market is segmented into oral & parental, and intravenous. The oral & parental segment is anticipated to hold a significant share of the Africa Malaria Treatment Market during the forecast period owing to severe cases of malaria may require hospitalization, and in such instances, parenteral medications are often preferred for faster and more effective treatment. Injectable drugs can be administered directly into the bloodstream, ensuring a rapid response in critical situations. Oral medications are generally more convenient for outpatient treatment, particularly in cases of uncomplicated malaria. Patient compliance is often higher with oral medications as they are self-administered, and the treatment can be completed at home. Both oral and parenteral medications are used in combination therapies to enhance treatment effectiveness and reduce the risk of drug resistance. Combination therapies are commonly recommended to address the multi-stage life cycle of the malaria parasite.

Africa Malaria Treatment Market – By Distribution Channel

Based on distribution channel, the Africa Malaria Treatment Market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies segment is anticipated to hold a significant share of the Africa Malaria Treatment Market during the forecast period owing to hospital pharmacies are equipped to provide a wide range of antimalarial medications, including specialized drugs for severe or complicated cases. This ensures that healthcare professionals have access to a diverse formulary to meet the specific needs of patients. Hospitals are the primary facilities for managing emergency and critical care situations related to severe malaria. Hospital pharmacies are essential for stocking and dispensing medications promptly in such situations, contributing to timely and effective treatment.

Africa Malaria Treatment Market – By End User

Based on End User, the Africa Malaria Treatment Market is segmented into hospitals, specialty clinics, home care and others. The hospitals segment is anticipated to hold a significant share of the Africa Malaria Treatment Market during the forecast period owing to hospitals are critical for treating severe cases of malaria, especially those that require intravenous (IV) or parenteral medications. The ability of hospitals to provide advanced medical interventions contributes to the overall effectiveness of malaria treatment. Malaria can lead to life-threatening complications, necessitating emergency and critical care services. Hospitals are equipped to handle such situations, providing immediate medical attention, monitoring, and interventions as needed.                                                        

Africa Malaria Treatment Market – By Country

The in-depth research report on the Africa Malaria Treatment Market covers several major countries across the Africa: South Africa, Nigeria, Algeria, Rest of Africa. The South Africa is projected to be the fastest-growing country in the Africa Malaria Treatment Market during the projected period owing to South Africa has a well-established healthcare infrastructure with a network of hospitals, clinics, and healthcare facilities. Access to healthcare services, including malaria diagnosis and treatment, contributes to the growth of the market. South Africa has access to a variety of antimalarial drugs, both oral and parenteral, for the treatment of malaria. The availability of these medications contributes to effective and timely treatment.                                                        

Competitive Landscape

Major players operating in the Africa Malaria Treatment Market include Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Bliss GVS Pharma Ltd. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In November 2023 - A regional competition regulator's recent clearance of a buyout of Cipla Quality Chemicals Ltd. has somewhat increased investor expectations at the Uganda Securities Exchange (USE). In Uganda, Cipla Quality Chemicals Limited is a well-known producer of antiretroviral medications, which are used to treat hepatitis, malaria, and tuberculosis. 

• In April 2023 - According to the vaccine's producer, Reuters, francophone nations are lining up to approve a new malaria vaccine that will be ready for purchase in 20 million doses this year. Nigeria's pharmaceuticals authority has followed Ghana's lead, and the two countries are now the first in the world to support the novel R21 vaccine, which was created by Oxford University scientists and is produced by Novavax and the Serum Institute of India.

Scope of the Report

By Treatment

• Prescription Medications

• Vaccines

• Diagnostic Tests

• Others

By Drug Type

• Branded

• Generic

By Route of Administration

• Oral and Parental

• Intravenous

By Distribution Channel

• Direct Tender

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

By End User

• Hospitals

• Specialty Clinics

• Home care

• Others

By Country

• South Africa

• Nigeria

• Algeria

• Rest of Africa